Connect with us

Hi, what are you looking for?


J&J Q1 earnings: ‘we feel very good about 2023’

Shares of Johnson & Johnson (NYSE: JNJ) opened down this morning after the consumer health and pharmaceutical company said it swung to a loss in its first financial quarter.

What resulted in a loss this quarter?

J&J faced a one-time $6.9 billion charge this quarter to settle lawsuits that accused is talc containing powders of causing serious illnesses, including cancer and asbestos poisoning.

On the plus side, though, CFO Joseph Wolk confirmed that the consumer wasn’t pushing back on price increases. Speaking with CNBC’s Becky Quick, he added:

We continue to manage our costs and resources in a very practical, efficient way to make sure that we invest heavily in research and development.

Year-to-date J&J stock is down about 10% at writing.

Dividend and future guidance

Also on Tuesday, Johnson & Johnson raised its quarterly dividend by a little over 5.0% to $1.19 a share. Updating on the company’s recent Abiomed acquisition, the finance chief said:

We’ve been able to integrate seamlessly the Abiomed acquisition from last year. That business grew 22% from when it was a standalone a year ago. We continue to make great progress with our consumer health unit separation.

For the full year, the multinational raised its guidance today to between $10.60 and $10.70 of adjusted per-share earnings on up to $98.9 billion in sales.

Wall Street currently has a consensus overweight rating on J&J stock.

Notable figures in JNJ Q1 earnings report

Lost $68 million that translates to 3 cents per share

That compared to $5.149 billion of net income last year

Adjusted EPS printed at $2.68 as per the press release

Sales went up 5.6% year-on-year $24.746 billion

Consensus was $2.50 a share on $23.599 billion revenue

Johnson & Johnson noted meaningful sales growth in all three of its business segments. According to CFO Wolk:

Great scientific innovation continues to produce great financial results for our company. We’ve been able to manage some of the macroeconomic headwinds. We feel very good about 2023 and beyond.

The post J&J Q1 earnings: ‘we feel very good about 2023’ appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    As the United States continues to grapple with the ongoing immigration crisis, the House and Senate have found themselves at odds over how to...

    Latest News

    As the world continues to grapple with the COVID-19 pandemic, the global economy is facing unprecedented challenges. In the United States, President Joe Biden...

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 All Rights Reserved.